5 results
To assess whether testing for fibronectin is a cost-effective strategy that prevents unnecessary treatment in women with threatened preterm labour.
Primary:to evaluate the effects of a moderate CYP3A4/5 inhibitor, diltiazem on the pharmacokinetics and pharmacodynamics (Thrombin and TRAP-induced platelet aggregation) of the study drug and its known metabolitessecundary:to evaluate the effects of…
To assess whether in women with early PPROM tocolytics improve perinatal outcome.
To evaluate the effectiveness of tocolytic maintenance therapy for postponing delivery after initial 48-hour tocolytic therapy in women with threatened preterm birth from 24-32 weeks gestational age.
Primary:To demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks compared to remaining on ABC/DTG/3TC (or DTG and an approved dual-NRTI scheme) over 48 weeks.Secondary:To…